Mitiglinide

 Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]

Mitiglinide
Mitiglinide.svg
Clinical data
Trade namesGlufast
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth (tablets)
ATC code
  • A10BX08 (WHO)
Identifiers
IUPAC name
  • (−)-(2S,3a,7a-cis)-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid
CAS Number
  • 145375-43-5 ☒
PubChem CID
  • 121891
DrugBank
  • DB01252 check
ChemSpider
  • 108739 check
UNII
  • D86I0XLB13
KEGG
  • D01854 check
ChEMBL
  • ChEMBL471498 check
CompTox Dashboard (EPA)
  • DTXSID4048303 Edit this at Wikidata
Chemical and physical data
FormulaC19H25NO3
Molar mass315.413 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
InChI
  • InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 check
  • Key:WPGGHFDDFPHPOB-BBWFWOEESA-N check
 ☒check (what is this?)  (verify)

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

PharmacologyEdit

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

DosageEdit

Mitiglinide is delivered in tablet form.

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.